Kalvista Pharmaceuticals Announced Its Strategic Plans For Fiscal Year 2025, Beginning May 1, Including For Sebetralstat, The Company's Investigational Novel, Oral Plasma Kallikrein Inhibitor For The On-demand Treatment Of Hereditary Angioedema
Kalvista Pharmicals宣布了自5月1日起的2025财年的战略计划,其中包括该公司用于按需治疗遗传性血管性水肿的新型口服血浆Kallikrein抑制剂Sebetralstat的战略计划